For instance, the pan-PKD inhibitor CRT0066101 (CRT) is a potent and selective small-molecule inhibitor of PKD, originally developed for its anti-proliferative and anti-inflammatory properties in cancer and immune-related disorders, which has shown efficacy both in vitro and in vivo against various human malignancies (Harikumar et al., 2010; Li et al., 2018; Cui et al., 2023). The gene discussed is PRKD1; the disease is cancer.